Frontline Indian pharmaceutical firms want the United States Trade Representative (USTR) to take India off the Priority Watch List in its annual Special 301 Report in view of the “strides” made towards an improved intellectual property rights (IPR) regime and to sustain this “forward momentum”.
These firms claim that “administrative improvements” in patent issuance and enforcement demonstrated in 2015 and 2016 have been sustained and...





